GlassScriptPhysician profile
Peter K Stoyanov
NPI 1639542517
$1,569.52
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $151 · 2022: $730 · 2023: $553 · 2024: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $642 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $641.83 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $437.12 | 2021-2023 | Rexulti, Abilify Maintena |
| Abbvie INC. | $383.19 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $162.77 | 2022-2023 | Caplyta |
| Alkermes, INC. | $116.92 | 2022-2024 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $95.85 | 2022-2023 | Trintellix |
| Supernus Pharmaceuticals, INC. | $95.54 | 2021-2022 | |
| Tempus Ai, INC | $68.43 | 2024 | |
| Idorsia Pharmaceuticals US INC | $48.26 | 2022-2023 | Quviviq |
| Bausch Health US, LLC | $44.07 | 2022-2023 | Aplenzin, Wellbutrin |
| Axsome Therapeutics, INC. | $39.85 | 2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $35.34 | 2023 | Fanapt, Hetlioz |
| Corium, LLC | $21.64 | 2023 | Azstarys |
| Ironshore Pharmaceuticals INC. | $20.54 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Stoyanov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.